Published in J Virol on July 01, 1992
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol (1997) 2.11
Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol (1997) 2.08
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol (1998) 1.81
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A (1993) 1.77
Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol (1997) 1.75
Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol (1996) 1.55
Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol (1998) 1.53
In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J Virol (1994) 1.50
Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. J Virol (1993) 1.46
Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol (1995) 1.43
Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin). J Virol (1997) 1.41
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol (2003) 1.40
The "V3" domain is a determinant of simian immunodeficiency virus cell tropism. J Virol (1994) 1.40
Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol (1995) 1.35
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol (1999) 1.31
Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest (2000) 1.29
Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. J Virol (1999) 1.20
Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol (2001) 1.18
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol (1999) 1.16
Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. J Virol (1993) 1.15
Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol (2004) 1.15
Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog (2011) 1.15
Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype. J Virol (1995) 1.13
Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol (1995) 1.10
Evolution of CCR5 use before and during coreceptor switching. J Virol (2008) 1.09
Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data. PLoS Comput Biol (2012) 1.00
Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol (2006) 0.98
R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol (2008) 0.97
Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J Virol (2010) 0.93
Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1. J Virol (1995) 0.92
The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Proc Biol Sci (1998) 0.88
Coreceptor use in nonhuman primate models of HIV infection. J Transl Med (2011) 0.87
Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One (2011) 0.86
A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressure. J Virol (2000) 0.86
A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity (2016) 0.85
SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol (2010) 0.83
Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. J Virol (1999) 0.82
Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology (2012) 0.80
Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model. J Virol (1998) 0.77
Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques. J Virol (1994) 0.76
Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count. Clin Diagn Lab Immunol (2000) 0.75
On the Physicochemical and Structural Modifications Associated with HIV-1 Subtype B Tropism Transition. AIDS Res Hum Retroviruses (2016) 0.75
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol (1991) 4.37
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol (1991) 2.40
The role of the V3 loop of gp120 in HIV infection. AIDS (1991) 2.23
Amino acid composition and the evolutionary rates of protein-coding genes. J Mol Evol (1985) 2.00
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Antigenic diversity thresholds and the development of AIDS. Science (1991) 5.13
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (1993) 3.62
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (1988) 3.50
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology (1991) 3.33
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ (1989) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virology (1992) 2.76
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Neutralization of HIV-1: a paradox of humoral proportions. FASEB J (1991) 2.41
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Universal cellular tropism? Nature (1992) 2.18
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J Virol (1996) 2.17
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology (1994) 2.15
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics (1986) 2.09
Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health (1988) 2.07
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06
Alternative view on AIDS. Lancet (1992) 2.06
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol (1982) 2.04
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol (2001) 1.98
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J Infect Dis (1993) 1.95
HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. Genitourin Med (1989) 1.88
Estimating relative fitness in viral competition experiments. J Virol (2000) 1.87
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother (1996) 1.85
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology (1991) 1.85
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol (1999) 1.81
Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest (1992) 1.81
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol (2001) 1.79
Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. Virology (1997) 1.79
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A (1993) 1.77
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev (1994) 1.73
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Detecting dinosaur DNA. Science (1995) 1.69
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis (1999) 1.61
AIDS pathogenesis: a dynamic interaction between HIV and the immune system. Immunol Today (1990) 1.60